Skip to main content
. 2024 Feb 28;13(2):321–333. doi: 10.21037/tlcr-23-804

Figure 4.

Figure 4

The activation of multiple signaling pathways, including HER3, induced by HRG1 treatment, and the effects of ALK- or EGFR-tyrosine kinase inhibitors in H3122 (EML4-ALK variant 1) and H2228 (EML4-ALK variant 3a/b) cell lines. Cells were pre-treated with HRG1 (10 nM) for 4 hours followed by lorlatinib (Lor), Erlotinib (Erl), or a combination of both for 2 hours. ALK, anaplastic lymphoma kinase.